Daniel Dornbusch

Company: Excision BioTherapeutics Inc.

Job title: Chief Executive Officer

Seminars:

Applying CRISPR-based Therapeutic Technology to Treat Viral Infectious Diseases 2:30 pm

Explore the advantages of applying gene editing therapies outside of rare disease Define how Excision’s CRISPR approach allows for the excision of large sections of viral DNA to eliminate multiple viral genes Understand the strategies and approaches which allow for the EBT-101 program to reach clinical trialsRead more

day: Day Two